Treatment with an AXL inhibitor, MP470 (an AXL, PDGFRa, ckit inhibitor; SuperGen, Dublin, CA, USA) reduced the ability of breast cancer stem cells to form mammospheres and improved tumor cell sensitivity to chemotherapy [78]. This evidence concerns the gene AXL and breast cancer.